DiGeronimo v. UNUM Life Insurance Companies of America

CourtDistrict Court, N.D. Ohio
DecidedAugust 27, 2025
Docket1:22-cv-00773
StatusUnknown

This text of DiGeronimo v. UNUM Life Insurance Companies of America (DiGeronimo v. UNUM Life Insurance Companies of America) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
DiGeronimo v. UNUM Life Insurance Companies of America, (N.D. Ohio 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION

DONALD DIGERONIMO, Case No. 1:22-cv-00773

Plaintiff, -vs- JUDGE DAVID A. RUIZ

UNUM LIFE INS. CO. OF AMERICA, et al., Memorandum Opinion and Order Defendants.

Now pending is Plaintiff’s Motion for Discovery, moving the Court for an order requiring Defendant to respond to proposed Interrogatories, Requests for Production of Documents, and Requests for Admissions. (R. 24, PageID# 4685). Plaintiff additionally requested an order to permit a future deposition of any medical or vocational reviewer identified in the interrogatory response(s). Id. Defendant filed a Brief in Opposition to Plaintiff’s Motion for Discovery. (R. 25). Plaintiff filed a Reply in Support of the Motion for Discovery. (R. 26). For the reasons stated below, the Court denies Plaintiff’s motion. I. Facts Plaintiff was employed by Independence Excavating (“Independence”). (R. 14, PageID# 200-201). Nearly twenty years ago, in September of 2004, Plaintiff began treatment with Nancy Foldvary-Schaefer, D.O., for epilepsy. (R. 14-1, PageID# 172–174). He underwent a right temporal lobe resection two years earlier. (R. 14-1, PageID# 172). On August 20, 2020, Plaintiff applied for long term disability (LTD) benefits due to epilepsy related seizures. (R. 14-1, PageID# 275-276). Dr. Foldvary-Shaefer’s opinion on July 28, 2020, indicated “No use of heavy equipment/machinery, avoid heights/climbing, [and] avoid sharp moving objects/equipment” due to “seizures with confusion, altered mental state/cognition, stress, especially as his job is main trigger for seizure occurrences.” (R. 14-1, PageID# 173-174). The restrictions were indicated to have begun in 2004 and extended to the “present [year 2020], ongoing.” Id. at PageID# 173. A letter

authored by Dr. Foldvary-Schaefer just a few months later—on October 14, 2020—stated as follows: Mr. Digeronimo primarily experiences nocturnal seizures which disrupt his sleep pattern. He has difficulty falling back to sleep after seizures and is therefore sleep deprived in the morning. Sleep deprivation results in impaired cognitive functioning and increased stress through out the next day. Known aura/seizure triggers for Mr. Digeronima [sic] are sleep deprivation and job duty stress. The combination of nocturnal seizures, sleep deprivation, cognitive impairment and increased job stress are the findings that support his inability to fulfill job responsibilities.

(R. 14-1, PageID# 785). On October 22, 2020, Defendant’s in-house physician consultant, Joseph A. Antaki, M.D., contacted Dr. Foldvary-Schaefer’s office and spoke to a nurse, who clarified that Plaintiff has nocturnal seizures, which do not require a driving restriction; the nocturnal seizures result in impaired cognition the following day; and Plaintiff was last seen on July 28, 2020 with no changes in treatment at that time. (R. 14-2, PageID# 804-805). Dr. Antaki noted that Plaintiff’s most recent brain MRI was considered “stable” without an indication for further tumor treatment, Plaintiff’s KPS (Karnofsky Performance Status-used in assessments of those with cancer) scale was “90,” which was consistent with an ability to carry on normal activity and work.” (R. 14-2, PageID# 808). 2 On October 28, 2020, outside physician consultant Michael Chilungu, M.D., reviewed Plaintiff’s file and came to the following conclusion: Based on the available information, clinical evidence does not support functional neurologic impairment during the period under review.

The claimant has complained of symptoms of recurrent, primarily nocturnal seizures, as a cause of occupational impairment. The claimant’s medical providers, Neurologist Dr. Fodvary Shaefer [sic], has similarly argued that the claimant is impaired based on the above concern, opining that the claimant has difficulty falling asleep afterwards, with residual cognitive effects from disrupted sleep.

The available information related to the claimant’s neurologic physical examinations, however, reveal no evidence of significant abnormalities on medical examination that would lead to concerns for significant neurologic functional impairment. The claimant demonstrates consistently unremarkable neurological examinations throughout the medical record. Although the claimant demonstrates evidence of underlying epilepsy on EEG testing, his seizures occur mostly after- hours, are brief, and reportedly nocturnal. On 7/28/2020 the claimant’s seizures are described as mostly consisting of him staring for 30 seconds, and it is reported during that visit that his last seizure was 5 weeks prior. The claimant demonstrates stable neuroimaging findings of stable postsurgical changes and no evidence of brain tumor recurrence on brain MRI testing, dated 4/29/2020, that suggest disease stability throughout the medical record. No detailed cognitive testing is documented in the medical record to substantiate a claim that the claimant is cognitively impaired to such a degree as to preclude occupational involvement. Routine neurologic testing reveals normal gross cognition. Although travel is a material function of the claimant’s occupation, the claimant reportedly is not under driving restrictions, due to the nocturnal nature of his seizures. On the basis of the above, I am in agreement with the OSP that there is insufficient evidence to assert that the claimant lacks the ability to function in a full-time occupation at the above described level of exertion.

(R. 14-2, PageID# 817). On November 5, 2020, Plaintiff’s claim for LTD benefits was denied. (R. 14-1, PageID# 842-848). Plaintiff submitted an appeal on December 16, 2021, along with his own affidavit, an opinion from Dr. Foldvary-Schaefer from October 28, 2021, a vocational report from Kathleen Reis, and medical records from the Cleveland Clinic spanning over twenty years. (R. 14-1, PageID# 3 1006). Dr. Foldvary-Schaefer’s letter stated that Plaintiff had been treated with multiple medications and two temporal lobectomy procedures in hopes to control his seizures, but “he continues to have persistent daytime and night time seizures… triggered by stress and lack of sleep.” (R. 14-2, PageID# 1026). Post-seizure recovery periods can last 24-48 hours, and symptoms during this time could include lethargy and confusion. Id. It was Dr. Foldvary-Schaefer’s opinion that Plaintiff “would be unable to maintain any employment on a full-time basis due to being off- task at least 20% of an eight hour work day and because of issues with absenteeism of at least three

to four times per month.” She continued that Plaintiff’s limitations included “no arbitration, confrontation, negotiation, frequent interaction with others for full-time work, and absolutely no work involving him being responsible for the health, safety, or welfare of others.” Id. On January 28, 2022, physician consultant Scott B. Norris, M.D., reviewed Plaintiff’s file and medical records—including letters from Dr. Foldvary-Schaefer received both before and after Plaintiff’s appeal—and concluded that medical evidence did not support Plaintiff having restrictions and/or limitations that would preclude the demands of his occupation. (R. 14-7, PageID# 4023-4025). On March 2, 2022, Ms. Reis authored a letter focusing on Plaintiff’s real estate investment

business. (R. 14-7, PageID# 4065-4067). She indicated that Plaintiff’s work in this regard is “fully accommodated … that is in no way equivalent to regular competitive employment” and “is performed on an irregular, idiosyncratic, seizure-event-based schedule.” Id. at PageID# 4067. On March 4, 2022, Dr. Foldvary-Schaefer wrote a brief four-sentence letter that merely disagreed with the medical reviewers conclusions, and stated that she “stands by” her initial opinion

4 of October 28, 2021. (R. 14-7, PageID# 4064). No explanation is contained in the letter for Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
DiGeronimo v. UNUM Life Insurance Companies of America, Counsel Stack Legal Research, https://law.counselstack.com/opinion/digeronimo-v-unum-life-insurance-companies-of-america-ohnd-2025.